28A-1091020
US provisional
FRIL is a lectin isolated from the seeds of Lablab purpureus with potent antiviral activity against multiple pathogens. However, the differentially-digested connecting loop between alpha and beta subunits of this lectin may impede its function, introduce heterogeneity, and plant-specific N-glycosylations including beta1,2-xylose may induce unwanted immunogenicity when FRIL is used therapeutically. In this invention, we describe molecular engineering methods to enhance FRIL’s antiviral effect and decrease antigenicity, either through enzymatic cleavage of its alpha-beta connecting loop on a native plant-purified protein, or molecular cloning of FRIL to engineer specific cleavage sites onto the alpha-beta connecting loop for easier cleavage.
- Molecularly engineered FRIL has higher antiviral potency than the native form of FRIL
- Molecularly engineered FRIL lack plant-specific N-glycans that exist on its native form, which is known to cause unwanted immunogenicity in vivo
- Recombinant FRIL offers additional benefits in production scalability and mutagenesis.
- Molecularly engineered FRIL may be utilized in the treatment of various virus infections, either by injection or nasal spray
- Molecularly engineered FRIL can be sprayed/coated onto various instruments and personal protective equipment to prevent viral transmission
Che Alex Ma
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Molecular engineering of Flt3 receptor-interacting lectin (FRIL) and its uses thereof